IP Library Granted Patent US 10,254,297
Granted Patent B2
US 10,254,297 · App. 15/200,558 · Granted Apr 9, 2019

Assay for methoxetamine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,254,297
App. No.
15/200,558
Granted
Apr 9, 2019
Kind
B2
Abstract

Components for enabling immunodetection of methoxetamine are described including immunogens, haptens, antibodies and kits.

Claims (14)

1. A polyclonal antibody raised against an immunogen having the structure of:

wherein KLH is keyhole limpet hemocyanin,

wherein the polyclonal antibody binds to methoxetamine and N-desethylmethoxetamine, wherein the polyclonal antibody has a cross-reactivity of 24% for N-desmethylmethoxetamine, when compared to 100% cross-reactivity for methoxetamine and shows a cross-reactivity of less than 5.0% for each of ketamine, norketamine, phencyclidine, tramadol and tilidine, when compared to 100% cross-reactivity for methoxetamine; and

wherein said cross reactivity is measured by using N-(5-carboxypentyl)-N-desethylmethoxetamine-HRP as a detecting agent, wherein HRP is horseradish peroxidase.

2. The polyclonal antibody of claim 1 which has an IC 50 of <1.00 ng/ml for methoxetamine.

3. The polyclonal antibody of claim 1 , which has been purified.

4. A method of detecting or determining methoxetamine in a sample comprising:

i) contacting the sample with a detecting agent and the polyclonal antibody of claim 1 ; and

ii) detecting or determining the amount of the detecting agent bound to the antibody.

5. The method of claim 4 in which the detecting agent is N-(5-carboxypentyl)-N-desethylmethoxetamine-HRP.

6. The method of claim 5 , wherein the presence of the detecting agent is detected or determined by a colour change in response to reaction of HRP with a substrate.

7. The method of claim 6 , wherein the colour change is detected or determined by reading the absorbance at 450 nm.

8. A kit comprising the polyclonal antibody of claim 1 .

9. The kit of claim 8 , further comprising a detecting agent, wherein the detecting agent N-(5-carboxypentyl)-N-desethylmethoxetamine-HRP.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVENYANCE PREVIOUSLY RECORDED AT REEL: 055950 FRAME: 0471. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 20, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 056210/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 055950/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2017
From: MCCONNELL, IVAN; LOWRY, PHILIP; BENCHIKH, ELOUARD; FITZGERALD, PETER
To: RANDOX LABORATORIES LIMITED
Reel/Frame 042615/0782 →